Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies

Abstract excerpt

Importance: Although differences in the prevalence of key cancer-specific somatic mutations as a function of genetic ancestry among patients with cancer has been well-established, few studies have addressed the practical clinical implications of these differences for the growing number of biomarker-driven treatments. Objective: To determine if the approval of precision oncology therapies has benefited patients...

Topics

Join the communities discussing this publication.

• Cancer Genomics and Diagnostics
• Genomics and Rare Diseases
• Lung Cancer Treatments and Mutations